(Q24244700)

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Buprenorphine vs. morphine via the epidural route: a controlled comparative clinical study of respiratory effects and analgesic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Defining the clinically important difference in pain outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Clinically important changes in acute pain outcome measures: a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Morphine and alternative opioids in cancer pain: the EAPC recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Cancer breakthrough pain characteristics and responses to treatment at a VA medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Breakthrough pain: definition, prevalence and characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Breakthrough pain: characteristics and impact in patients with cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

Pharmacotherapy of cancer-related episodic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

A prospective multicenter assessment of the Edmonton staging system for cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

7 January 2021

Clinically important changes-what's important and whose change is it anyway?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

7 January 2021

Rescue factor: A design for evaluating long-acting analgesics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

7 January 2021

A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

7 January 2021

Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004311.PUB2

7 January 2021